摘要
我们研究DTPA-bis(蛋氨酸)的潜在作用,它是一种靶标特定的氨基酸探针,可使用多峰性成像技术检测在增殖肿瘤中过度表达的L-型氨基酸转运蛋白(LAT1)。它的配体,DTPA-bis(Met)容易转化为镧系配合物,且使用多峰性成像能够发现其靶向癌细胞。DTPA-bis(Met)配合物可被合成和被质谱表征。MR纵向弛豫, r1=4.067 ± 0.31 mM-1s-1 和横向弛豫,r2= 8.61 ± 0.07 mM-1s-1of Gd(III)-DTPA-bis(Met) 在 pH 7.4 和 7T下被检测。 Eu(III)-DTPA-bis(Met) 的光亮和局部荧光在标准显微镜下观察,位移研究表明配体功能。 Eu(III)-DTPA-bis(Met) 在U-87MG cells中的 KD值为17.3 pM,显示在细胞内有明显的荧光。放射HPLC显示68Ga(III)-DTPA-bis(Met) 的放射化学纯度超过 95% (具体活力 = 400-500 MBq/μmol, 标记效能 78 %)。用68Ga(III)-DTPA-bis(Met)和未标记的L-蛋氨酸对移植瘤的U-87MG无胸腺鼠的预处理使在Micro PET中的肿瘤摄入减少10倍。这些数据支持 68Ga(III)-DTPA-bis(Met)和 LAT1转运蛋白的特定绑定。总之,这种药物在生物环境中具有高度稳定性,并与在肿瘤区域高度积累的、高肿瘤/非肿瘤比率和体内非特定存留的LAT1转运蛋白间具有有效的相互作用。
关键词: 荧光,镧系,LAT1,蛋氨酸,PET成像。
图形摘要
Current Cancer Drug Targets
Title:LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Volume: 14 Issue: 9
Author(s): Puja Panwar Hazari, Surbhi Prakash, Virendra K. Meena, Ambika Jaswal, Harleen Khurana, Surabhi Kirti Mishra, Hemanth kumar Somu Bhonsle, Lokendra Singh and Anil K. Mishra
Affiliation:
关键词: 荧光,镧系,LAT1,蛋氨酸,PET成像。
摘要: We investigated the potential of DTPA-bis(Methionine), a target specific amino acid based probe for detection of L-type amino acid transporters (LAT1) known to over express in proliferating tumours using multimodality imaging. The ligand, DTPA-bis(Met) was readily converted to lanthanide complexes and was found capable of targeting cancer cells using multimodality imaging. DTPA-bis(Met) complexes were synthesized and characterized by mass spectroscopy. MR longitudinal relaxivity, r1=4.067 ± 0.31 mM-1s-1 and transverse relaxivity, r2= 8.61 ± 0.07 mM-1s-1of Gd(III)-DTPA-bis(Met) were observed at pH 7.4 at 7T. Bright, localized fluorescence of Eu(III)-DTPA-bis(Met) was observed with standard microscopy and displacement studies indicated ligand functionality. KD value determined for Eu(III)-DTPA-bis(Met) on U-87MG cells was found to be 17.3 pM and showed appreciable fluorescence within the cells. Radio HPLC showed a radiochemical purity more than 95% (specific activity = 400-500 MBq/μmol, labelling efficiency 78 %) for 68Ga(III)-DTPA-bis(Met). Pre-treatment of xenografted U-87MG athymic mice with 68Ga(III)-DTPA-bis(Met) following unlabelled L-methionine administration reduced tumour uptake by 10-folds in Micro PET. These data support the specific binding of 68Ga(III)-DTPA-bis(Met) to the LAT1 transporter. To summarize, this agent possesses high stability in biological environment and exhibits effective interaction with its LAT1 transporters giving high accumulation in tumour area, excellent tumour/non-tumour ratio and low non-specific retention in vivo.
Export Options
About this article
Cite this article as:
Puja Panwar Hazari , Surbhi Prakash , Virendra K. Meena , Ambika Jaswal , Harleen Khurana , Surabhi Kirti Mishra , Hemanth kumar Somu Bhonsle , Lokendra Singh and Anil K. Mishra , LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities, Current Cancer Drug Targets 2014; 14 (9) . https://dx.doi.org/10.2174/1568009614666141020102337
DOI https://dx.doi.org/10.2174/1568009614666141020102337 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Intravenous and Regional Paclitaxel Formulations
Current Medicinal Chemistry Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome
Anti-Cancer Agents in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design Apoptotic Effect of Novel Benzimidazole Derivatives Bearing Pyridyl/Pyrimidinyl Piperazine Moiety
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy An Automatic Glioma Segmentation System Using a Multilevel Attention Pyramid Scene Parsing Network
Current Medical Imaging Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium
Current Topics in Medicinal Chemistry Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Pretargeted Radioimmunotherapy with α-Particle Emitting Radionuclides
Current Radiopharmaceuticals